pH determination: pH determination with an electrode was found previously to correlate well with changes in the light absorbance at 560 nm reflecting changes in the pH indicator, phenol red [1] .
Glucose assay: Glucose was assayed in the cell culture medium using Kit GAGO-20 from Sigma-Aldrich, St. Louis, MO, USA. This is a colorimetric procedure in which the oxidation of glucose is coupled with glucose oxidase and peroxidase to the oxidation of dianisidine.
Statistical evaluation
Data are presented as means and standard deviations for six or a greater number of determinations. Statistical significance of the results was determined by a twotailed Student's t-test or by Dunnett's test for multiple comparisons. A probability of less than 5% was considered significant.
Results
Incubation of many colon cancer cell lines with 1 mM butyrate is known to inhibit growth and induce the activity of alkaline phosphatase. This is illustrated for Caco-2 ( Figure 1A and 1D), HT29 ( Figure 1B and 1E) and SW1116 cells ( Figure 1C and 1F). The activity of alkaline phosphatase is often used as a marker of differentiation in colon cancer cells. Growth inhibitory effects were also seen when these cell lines were incubated with 3PO ( Figure  1A , 1B and 1C), but this action was not accompanied by an increase in alkaline phosphatase activity ( Figure 1D , 1E and 1F). Additive effects on growth were seen when Caco-2 cells were incubated with a combination of 5 M 3PO and 1 mM butyrate ( Figure 1A ) and when HT29 and SW1116 cells were incubated with a combination of 10 M 3PO and 1 mM butyrate (Figure1B and 1C) .
The rapidly growing HCT116 colon cancer cells do not have significant alkaline phosphatase activity and activity was not induced by incubation with 1 mM butyrate (data not shown). However, growth inhibition was observed when HCT116 cells were incubated with 1 mM butyrate or 10 M 3PO (Figure 2A ). These actions were accompanied by decreased acidification of the medium ( Figure 2B ) and decreased glucose uptake ( Figure 2C ). Additive effects of combined incubation with 10 M 3PO and 1 mM butyrate were seen on growth, medium acidification and glucose uptake.
Inhibitory effects on growth were observed with 3PO and the biguanides, phenformin and metformin ( Figure 3A-D) . Additive effects with combined treatment with 3PO and a biguanide were more apparent with Caco-2, HCT116 and HT29 cells than with the more slowly growing SW1116 cells. Effects of 3PO and biguanides on medium acidification and glucose uptake are more readily observed in the more rapidly growing HCT116 and HT29 cells than the more slowly growing Caco-2 and SW1116 cells. Results for HCT116 and HT29 cells are shown in Figure 4A action of biguanides on glycolysis and glucose uptake was partially reversed by combined incubation with 10 M 3PO, which as a single agent tends to decrease medium acidification and glucose uptake.
The effect of combined treatment with 3PO and 2-deoxyglucose on growth and medium acidification is shown for Caco-2, HCT116 and HT29 cells in Figure 5A -F. Both compounds can exert inhibitory effects on glycolysis and additive inhibitory effects could be observed on growth and on medium acidification. That was also the case when a further combination of inhibitors of glycolysis, namely 3PO and 3-bromopyruvate was examined. The results for studies with Caco-2 and HCT116 cells are shown in Figure  6A -D.
Discussion
The tendency of cancer cells to have enhanced rates of glycolysis has been recognized since the early work of Warburg [5, 6] . Although this presents a potential target for chemotherapeutic intervention, the lack of specific inhibitors has been a long-standing problem. The recognition that fructose 2,6-bisphosphate is an important regulatory molecule for the activation of glycolysis directed attention to the bifunctional enzymes that control the level of that compound, the PFKFBs. A number of investigators have sought small inhibitory compounds for PFKFB3 [7] [8] [9] [10] on the basis that PKKFB3 activity is elevated in many types of cancer and has high phosphofructo-2-kinase activity [7, 11, 12] . Cancer chemotherapy is characterized by combination therapies that deter the development of resistance and may permit lower doses of individual compounds. Additive effects have been seen with 3PO and an inhibitor of autophagy against HCT116 human colon cancer cell lines [13] . In the present work, combinations have been studied of 3PO and some compounds that also inhibit glycolysis: butyrate, 2-deoxyglucose and 3-bromopyruvate. Butyrate is a nutrient for normal colonocytes. In addition, it is a broad-spectrum inhibitor of histone deacetylases and a differentiating agent for some cancer cell lines. 2-deoxyglucose is known to inhibit glycolysis after conversion to 2-deoxyglucose 6-phosphate but it can also affect mannose metabolism. It might be noted that 2-deoxyglucose is identical to 2-deoxymannose. 3-bromopyruvate has been widely studied since its identification as an inhibitor of tumor growth [14] . The action of 3-bromopyruvate has been attributed particularly to inhibition of hexokinase and glyceraldehyde-3-phosphate dehydrogenase but the compound may react with other cellular components. The low extracellular pH of tumors will favor the cytotoxicity of 3-bromopyruvate [15] .
In colon cancer cells the induction of alkaline phosphatase activity by butyrate has been used as a marker of differentiation. Increased alkaline phosphatase activity in response to butyrate treatment was seen in three of the colon cancer cells examined, Caco-2, HT29 and SW1116. It was not observed with HCT116 cells but those cells, like the others, were subject to growth inhibition when treated with butyrate. It is clear that the differentiating effect of butyrate does not have a simple relationship to growth inhibition. This observation was reinforced by the finding that there was no induction of alkaline phosphatase activity when growth was inhibited by incubation with 3PO.
The biguanides, metformin and phenformin, are unusual in as much as they can enhance glucose uptake and metabolism under conditions in which cell proliferation is inhibited. In previous work the enhanced glucose metabolism caused by the biguanides was found to be blocked by butyrate, 2-deoxyglucose and 3-bromopyruvate [2] . In the present work the effects of biguanides on glucose metabolism were reversed by coincubation with 3PO. Despite having opposing effects on glucose metabolism, 3PO and the biguanides could exert additive inhibitory effects on the growth of colon cancer cells.
3PO was the first commercially available PFKFB3 inhibitor. Related structures have been synthesized that are effective at lower concentrations [16] and work is ongoing to optimize pharmacokinetic and tumor-selective action. Attention is also being given to inhibitors of PFKFB4 [17] . The present work relates to combinations with effects on glucose metabolism and combination studies with chemotherapeutic agents with other modes of action may be anticipated. There is considerable current interest in targeting cancer metabolism as a therapeutic approach [18, 19] . For those tumors that are addicted to glucose metabolism, PFKFB3 inhibitors appear promising agents for combination therapy.
Conclusion
3PO was an inhibitor of proliferation of colon cancer cells, especially the rapidly growing HCT116 and HT29 cell lines. 3PO and related molecules may be useful agents in combination with other drugs that inhibit colon cancer cell proliferation. 
